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Abstract
Background: Dominantly inherited missense mutations in leucine-rich repeat kinase 2 (LRRK2) are the most
common genetic cause of Parkinson’s disease, but its normal physiological function remains unclear. We previously
reported that loss of LRRK2 causes impairment of protein degradation pathways as well as increases of apoptotic
cell death and inflammatory responses in the kidney of aged mice.
Results: Our analysis of LRRK2-/- kidneys at multiple ages, such as 1, 4, 7, and 20 months, revealed unique age-
dependent development of a variety of molecular, cellular, and ultrastructural changes. Gross morphological
abnormalities of the kidney, including altered size, weight, texture, and color, are evident in LRRK2-/- mice at 3-4
months of age, along with increased accumulation of autofluorescent granules in proximal renal tubules. The ratio
of kidney/body weight in LRRK2-/- mice is increased at 1, 4, and 7 months of age (~10% at 1 month, and ~20% at
4 and 7 months), whereas the ratio is drastically decreased at 20 months of age (~50%). While kidney filtration
function evaluated by levels of blood urea nitrogen and serum creatinine is not significantly affected in LRRK2-/-
mice at 12-14 months of age, expression of kidney injury molecule-1, a sensitive and specific biomarker for
epithelial cell injury of proximal renal tubules, is up-regulated (~10-fold). Surprisingly, loss of LRRK2 causes age-
dependent bi-phasic alterations of the autophagic activity in LRRK2-/- kidneys, which is unchanged at 1 month of
age, enhanced at 7 months but reduced at 20 months, as evidenced by corresponding changes in the levels of
LC3-I/II, a reliable autophagy marker, and p62, an autophagy substrate. Levels of a-synuclein and protein carbonyls,
a general oxidative damage marker, are also decreased in LRRK2-/- kidneys at 7 months of age but increased at 20
months. Interestingly, the age-dependent bi-phasic alterations in autophagic activity in LRRK2-/- kidneys is
accompanied by increased levels of lysosomal proteins and proteases at 1, 7, and 20 months of age as well as
progressive accumulation of autolysosomes and lipofuscin granules at 4, 7-10, and 20 months of age.
Conclusions: LRRK2 is important for the dynamic regulation of autophagy function in vivo.
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Background
Parkinson’s disease (PD) is the most common neurode-
generative movement disorder. The neuropathological
hallmarks of PD are progressive degeneration of dopa-
minergic neurons in the substantia nigra pars compacta
of the brain and the presence of intraneuronal
cytoplasmic inclusions known as Lewy bodies (LBs), in
which a-synuclein aggregates are a major component
[1,2]. Although most PD cases occur sporadically, at
least five genes (including a-synuclein, parkin, DJ-1,
PINK1,a n dLRRK2) associated with monogenetic famil-
ial forms of the disease mimicking clinical symptoms of
sporadic PD have been identified, permitting studies of
the pathogenic mechanisms of PD using genetic
approaches. Dominantly inherited missense mutations in
the leucine-rich repeat kinase 2 (LRRK2)g e n ea r et h e
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highlighting the importance of LRRK2 in PD pathogen-
esis. LRRK2 is a large protein of 2527 amino acid resi-
dues, consisting of several functional domains, including
a Ras-like small GTPase domain, a MAP kinase-like
domain, as well as several protein-protein interaction
domains, such as the leucine-rich repeat domain
[6,9,10]. The disease-associated mutations in LRRK2 are
present in all functional domains of the protein. Most
LRRK2 mutations causes clinically typical PD, but the
neuropathological features vary, ranging from pure
nigral degeneration without LBs to nigral degeneration
with brainstem or widespread LBs, or ubiquitin-positive
inclusions, or neurofibrillary tau-positive tangles [9,11].
Despite the disease relevance of LRRK2, its normal
physiological role remains elusive. Elucidation of LRRK2
functions will provide insights into how mutations in
LRRK2 lead to dopaminergic dysfunction and degenera-
tion. Although the dominant inheritance of missense
mutations and the lack of nonsense or deletion muta-
tions in LRRK2 are consistent with toxic gain-of-func-
tion pathogenic mechanisms, we generated LRRK2-/-
mouse models to study the normal physiological func-
tion of LRRK2 and to determine the consequence of
inhibiting LRRK2 function. Similar to other PD genetic
mouse models, such as a-synuclein transgenic [12-14],
parkin-/- [15,16], DJ-1-/- [17,18], PINK1-/- [19,20], and
LRRK2 transgenic and knockin mice [21-25], LRRK2-/-
brains did not develop overt dopaminergic degeneration
[26]. However, LRRK2-/- kidneys developed striking
age-dependent abnormalities that are relevant to PD
pathogenesis, such as impairment of protein degradation
pathways, apoptotic cell death, oxidative damage, and
inflammatory responses [26]. There was striking accu-
mulation and aggregation of a-synuclein and ubiquiti-
n a t e dp r o t e i n si nt h ek i d n e y so fLRRK2-/- mice at 20
months of age [26]. The autophagy-lysosomal pathway,
which has been implicated in various neurodegenerative
diseases with protein aggregation-related pathologies,
including Parkinson’s disease and Huntington’s disease
[27-30], was impaired in LRRK2-/- kidneys at 20 months
of age, as indicated by impaired conversion of LC3-I to
LC3-II, a reliable indicator of the autophagic activity
[31], and accumulation of p62, an autophagy substrate
[32]. Although these molecular and cellular changes are
observed only in the kidney but not in the brain of
LRRK2-/- mice, they are very similar to processes that
are thought to be involved in PD pathogenesis, making
LRRK2-/- kidneys a relevant and valuable in vivo model
to study the physiological function of LRRK2 and to
identify the downstream cellular and molecular
pathways.
In the current study, our detailed time course study
revealed an unexpected finding that loss of LRRK2
dysregulates the autophagy pathway in an age-depen-
d e n tb i - p h a s i cm a n n e r .T h ea u t o p h a g i ca c t i v i t yi se l e -
vated at young ages (e.g., 7 months) but reduced at an
old age (e.g., 20 months). Furthermore, this process is
accompanied by increased levels of lysosomal proteins
and proteases as well as age-dependent, progressive
accumulation of autolysosomes and lipofuscin granules.
Thus, subsequent impairment of autophagy function in
aged LRRK2-/- kidneys may be due to depletion of
autophagy machinery and accumulation of subcellular
structures containing undigested lysosomal components
during aging.
Results
Morphological and histological analyses of LRRK2-/-
kidneys at various ages
We recently reported that while LRRK2-/- mice did not
develop overt dopaminergic degeneration and neuro-
pathological changes in the brain up to two years of age,
loss of LRRK2 caused striking abnormalities in the kid-
ney, which normally expresses the highest level of
LRRK2 compared to other organs and tissues [26]. To
determine when LRRK2-/- kidneys first show morpholo-
gical changes, we performed age-dependent analysis of
LRRK2-/- mice. Because LRRK2-/- kidneys appear
grossly normal at 10 weeks of age [26], we performed
additional analysis at 4 and 7 months of age, and found
that initial discoloration and altered granular tissue tex-
ture became evident in the kidney of LRRK2-/- mice at
3-4 months of age (Figure 1A). Interestingly, the weight
and size of LRRK2-/- kidneys undergo bi-phasic changes
as the mice get older, with initial increases in weight
and size followed by subsequent drastic decreases at 20
months of age (Figure 1B). The male LRRK2-/- kidneys
appear to have more severe morphological abnormalities
(darker color and rougher surfaces), whereas female
mice exhibit more variation in the kidney weight and
size. We therefore used only male mice in all of the sub-
sequent analyses. In contrast to LRRK2-/- mice at 20
months of age, which show ~49% decrease in the ratio
of kidney/body weight compared with wild-type controls
[26], kidneys from LRRK2-/- mice at 1, 4, and 7 months
of age are larger in size and weigh more compared with
wild-type controls (~10% increase at 1 month and ~20%
i n c r e a s ea t4a n d7m o n t h si nt h er a t i oo fk i d n e y / b o d y
weight) (Figure 1B).
In addition to the gross morphological abnormalities
in LRRK2-/- kidneys beginning at 3-4 months of age, we
observed many small autofluorescent puncta in the
epithelial cells of the proximal tubules in the deep layer
of the renal cortex in LRRK2-/- mice at 4 months of
age, which became more evident and distributed more
widely at 7 months of age (Figure 1C). By 20 months of
age, the cytosolic regions of the epithelial cells of the
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Page 2 of 16Figure 1 Morphological and histological analyses of LRRK2-/- kidneys at various ages. A. Initial discoloration, enlarged size, and altered
granular tissue texture are observed in kidneys of male LRRK2-/- mice beginning at 3-4 months of age, the extent of abnormalities increases
with age. B. The ratio of kidney/body weight is significantly increased in male LRRK2-/- mice at the ages of 1, 4, and 7 months but decreased
drastically at 20 months of age. C. Autofluorescence in the epithelial cells of the proximal tubules of the renal cortex of LRRK2-/- mice.
Autofluorescent intracellular granules are more visible in the epithelial cells of the proximal tubules of LRRK2-/- kidneys at 7 months than 4
months of age. By 20 months of age, the cytosolic regions of the epithelial cells of the proximal tubules in the LRRK2-/- kidneys are occupied by
large but irregular structures showing strong autofluorescence. DAPI-stained nuclei are in blue. All scale bars: 20 μm.
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cent structures (Figure 1C) that are lipofuscin granules
[26]. These data suggest that undigested autofluorescent
materials accumulate in LRRK2-/- kidneys beginning as
early as 4 months of age.
Up-regulation of kidney injury molecule-1 (Kim-1) in
LRRK2-/- kidneys
We also assessed whether accumulation and aggregation
of proteins in the kidney caused any loss of renal func-
tion by measuring the levels of blood urea nitrogen
(BUN) and serum creatinine, a classical method of
assessing renal function [33]. There is no significant dif-
ference in the levels of BUN and serum creatinine
between LRRK2-/- mice and wild-type controls at 12-14
months of age (Figure 2A). The BUN-to-creatinine ratio,
which is used to determine the possible cause of acute
kidney injury, is also normal in LRRK2-/- mice (Figure
2A), suggesting that the renal filtration function is not
significantly affected in LRRK2-/- mice up to 12-14
months of age.
To assess whether the striking abnormalities observed
in LRRK2-/- kidneys caused any nephrotoxicity to
epithelial cells of proximal renal tubules, we examined
the levels of kidney injury molecule-1 (Kim-1 in rodents,
KIM-1 in human), a very sensitive and specific biomar-
ker for epithelial cell injury of proximal renal tubules in
various settings [33,34]. An increase in Kim-1 due to
kidney injury can occur before any significant increase
in serum creatinine [34]. Kim-1 is localized to proximal
tubule epithelial cells, and its expression is at a very low
l e v e li nn o r m a lk i d n e y sb u ti n c reases dramatically after
acute kidney injury [34]. Long-term expression of KIM-
1 is also observed in patients with chronic kidney
Figure 2 Kidney injury and functional assay of LRRK2-/- mice. A. Classical renal chemistry analysis shows normal levels of blood urea
nitrogen (BUN) and serum creatinine as well as the ratio of BUN to serum creatinine in LRRK2-/- mice at 12-14 months of age. B. Western
analysis shows dramatically increased levels of kidney injury molecule-1 (Kim-1), a tissue and urinary biomarker for renal injury, in RIPA buffer-
soluble fractions of LRRK2-/- kidneys at the ages of 1 and 7 months, which is also increased in RIPA buffer-insoluble fractions of LRRK2-/- kidneys
at 20 months of age, compared with wild-type controls. The Western blots of ERK1/2 or Ponceau S staining of the membranes are used as
loading control, as levels of both GAPDH and b-actin are altered in LRRK2-/- kidneys. ns, not significant; *, P < 0.05; ***, P < 0.001.
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kidney injury [33]. There was already a significant
increase in the level of Kim-1 in LRRK2-/- kidneys at
one month of age (Figure 2B), which then appeared
grossly normal. At 7 months of age, there was approxi-
mately 10-fold increase in the level of Kim-1 in
LRRK2-/- kidneys compared with wild-type controls
(Figure 2B), but this increase was much lower than that
in acute kidney injury models (> 500-fold up-regulation),
such as those induced by ischemia [34]. The increased
expression of Kim-1 in LRRK2-/- kidneys persisted to 20
m o n t h so fa g e( F i g u r e2 B ) .T h e s ed a t as u g g e s tt h a t
while renal function evaluated by measuring blood urea
nitrogen and serum creatinine appears normal,
LRRK2-/- mice sustain chronic kidney injury, as indi-
cated by 10-fold up-regulation of kidney injury mole-
cule-1.
Age-dependent bi-phasic alterations of autophagic
activity in LRRK2-/- mice
To better understand the molecular mechanism under-
lying age-dependent protein accumulation and aggrega-
tion in the kidney of LRRK2-/- mice, we further
investigated the effect of LRRK2 deletion on the autop-
hagy-lysosomal pathway, one of the major protein
degradation pathways. Autophagy is often referred to as
macroautophagy, the major type of autophagy, by which
long-lived or damaged proteins and organelles together
with part of the cytoplasm are first enclosed by double-
membrane structures to form autophagosomes, which
then fuse with lysosomes to form autolysosomes and the
cargo delivered by autophagosome gets degraded by
lysosomal acid hydrolases and recycled back to the cyto-
plasm [27-30,35]. We previously reported that the
autophagy-lysosomal pathway was impaired in LRRK2-/-
kidneys at 20 months of age [26], as indicated by accu-
mulation of lipofuscin granules as well as impaired con-
version of non-lipidated form (LC3-I) to lipidated form
(LC3-II) of microtubule-associated protein 1 light chain
3 (LC3), a reliable indicator for autophagosome forma-
tion [31], and accumulation of p62, an autophagy sub-
strate [32]. Surprisingly, Western analysis showed higher
levels of LC3-II and lower levels of LC3-I in LRRK2-/-
kidneys at 7 months of age, as well as lower levels of
p62 (Figure 3). There were no significant alterations in
the levels of LC3 and p62 in the brain of LRRK2-/- mice
compared to wild-type controls at 20 months of age
(data not shown). These data suggest the increased con-
version of LC3-I to LC3-II and enhanced autophagic
activity (i.e., increased protein degradation) in the
LRRK2-/- kidneys at 7 months of age, which were oppo-
site to those at 20 months of age (Figure 3).
Western blotting also revealed an increased conver-
sion of form I to form II of Golgi-associated ATPase
enhancer of 16 kDa (GATE-16), which is a homolog of
LC3 and has also been reported to localize to autopha-
gosomal membrane upon form-II formation [36], in
LRRK2-/- kidneys at 7 months of age, further confirm-
ing enhanced autophagic activity. By 20 months of age,
both forms I and II of GATE-16 were decreased in kid-
neys of LRRK2-/- mice (Figure 3). These results indicate
that loss of LRRK2 in vivo increases autophagic activity
initially followed by subsequent decreases of autophagic
activity.
Age-dependent bi-phasic alterations of a-synuclein levels
in LRRK2-/- kidneys
a-Synuclein has been reported to be degraded at least in
part through the autophagy-lysosomal pathway, and
especially the clearance of a-synuclein aggregates is
highly dependent on the autophagy-lysosomal pathway
[27,30]. We therefore measured levels of a-synuclein in
both soluble and insoluble fractions of LRRK2-/- and
control kidneys at the ages of 1, 7, and 20 months by
Western blotting using a specific a-synuclein antibody,
which had been tested previously using samples from a-
synuclein-/- mice [37] and from transgenic mice overex-
pressing a-synuclein [23]. We found that while at the
ages of 1 and 7 months there was little a-synuclein that
was detectable by Western blotting in the RIPA buffer-
soluble fraction of the kidneys of both LRRK2-/- mice
and wild-type controls (data not shown), the levels of
high-molecular-weight species that were immunoreac-
tive for a-synuclein were reduced by approximately 40%
in the RIPA buffer-insoluble fractions of LRRK2-/- kid-
neys at 7 months of age compared with wild-type con-
trols, though no difference was found between the
genotypes at 1 month of age (Figure 4). By 20 months
of age, there were huge accumulation (~60-fold) of a-
synuclein in the RIPA buffer-soluble fractions and sig-
nificant increases (~1-fold) of high-molecular-weight a-
synuclein-immunoreactive species in the RIPA buffer-
insoluble fractions of LRRK2-/- kidneys (Figure 4) [26].
Thus, levels of a-synuclein were normal in LRRK2-/-
kidneys at 1 month of age, decreased at 7 months, and
increased at 20 months. These results are consistent
with other markers of autophagy function (Figure 3) and
indicate that autophagic activity is enhanced in
LRRK2-/- kidneys at 7 months of age but impaired by
20 months of age.
Age-dependent bi-phasic alterations of oxidation levels in
LRRK2-/- kidneys
Autophagy can be regulated by oxidative stress and oxi-
dized proteins are degraded via the autophagy-lysosomal
pathway [28,38-40]. The levels of protein carbonyls, a
general marker of oxidative damage, was dramatically
increased in the kidneys of LRRK2-/- mice at 20 months
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Page 5 of 16Figure 3 Loss of LRRK2 causes age-dependent bi-phasic alterations of autophagy markers or substrates. Western analysis shows bi-
phasic alterations of proteins (LC3-I and -II, GATE-16 (#, form I; ##, form II)) involved in the autophagy-lysosomal pathway as well as autophagy
substrate (p62) in the kidney of LRRK2-/- mice at the ages of 7 and 20 months compared with their respective wild-type (+/+) controls. Western
blots shown were obtained using RIPA buffer-insoluble fractions. The overall contrast and brightness for the GATE-16## panel were adjusted to
make the band more visible, since the level of GATE-16 form II is much lower than that of GATE-16 form I. In the bar-graph showing
quantification of proteins, the data for LC3-II and form II of GATE-16 from 7 months of age are not included, as these proteins are not detectable
in WT controls under these conditions. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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lipofuscin granules, which are composed of undigested
materials after lysosomal degradation containing oxi-
dized lipids, carbohydrates, and proteins, and are unde-
graded aggregates as a result of excessive oxidation and
crosslinking [38]. However, LRRK2-/- kidneys at 7
months of age showed a decreased oxidation level, indi-
cated by the reduced levels of protein carbonyls in the
RIPA buffer-insoluble fractions of the kidneys (Figure
5). There was no significant difference in the levels of
protein carbonyls in both RIPA buffer-soluble and -inso-
luble fractions of LRRK2-/- kidneys at one month of age
(Figure 5). These results are consistent with increased
intracellular degradation of oxidized proteins due to
enhanced autophagic activity in LRRK2-/- kidneys at 7
months of age.
Accumulation of lysosomal proteins/proteases and
autolysosomes in LRRK2-/- mice
Autophagy and lysosomes are closely linked in their
involvement in degradation of damaged molecules and
organelles [28,31,41,42]. We therefore measured levels
of lysosomal proteins and proteases in LRRK2-/- kidneys
at 1, 7, and 20 months of age (Figure 6). Western
Figure 4 Loss of LRRK2 causes age-dependent bi-phasic alterations of a-synuclein. Representative Western blots show that while there is
no significant difference in the levels of a-synuclein between LRRK2-/- mice and wild-type (+/+) controls at one month of age, high-molecular-
weight (HMW) a-synuclein-immunoreactivity is significantly decreased in the RIPA buffer-insoluble fractions of LRRK2-/- kidneys at 7 months of
age, suggesting increased degradation of a-synuclein. The level of HMW a-synuclein immunoreactivity is increased dramatically in the RIPA
buffer-insoluble fractions of LRRK2-/- kidneys at 20 months of age, suggesting increased aggregation of a-synuclein. The specificity of the a-
synuclein antibody had been confirmed previously using samples from a-synuclein-/- mice [37] and were confirmed again using samples from
multiple independent lines of a-synuclein-overexpressing transgenic mice [14,23]. ns, not significant; *, P < 0.05; **, P < 0.01.
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associated membrane proteins LAMP-1 (Figure 6A) and
LAMP-2 (data not shown) in the kidneys of LRRK2-/-
mice at 1, 7, and 20 months of age. Levels of lysosomal
proteases cathepsins B and D (both proforms and active
forms) are also elevated in LRRK2-/- kidneys (Figure
6A). Immunohistochemical analysis showed increased
immunoreactivity of cathepsin B in LRRK2-/- kidneys at
both 7 and 20 months of age, which appeared mostly
clustered at granular structures (Figure 6B).
We further performed electron microscopy analysis of
LRRK2-/- and wild-type kidneys at the ages of 4, 7, 9-
10, and 20 months, and found age-dependent
accumulation of electron-dense autolysosomes in the
epithelial cells of proximal tubules of LRRK2-/- kidneys
(Figure 7). Autolysosome is an organelle derived from
the fusion of an autophagosome and a lysosome, and is
where proteins and organelles are digested [28,31,41,42].
At 4 months of age, the presence of a large number of
electron-dense autophagosome-like structures as well as
autolysosome-like structures was already evident in
LRRK2-/- kidneys and such structures were absent in
wild-type kidneys (Figure 7A, B, G, &7H). At the ages of
7 months (Figure 7C, D, I, &7J) and 9-10 months (data
not shown), autophagosome-like structure as well as
autophagic vacuoles that were being formed and
Figure 5 Loss of LRRK2 causes age-dependent bi-phasic alterations of protein carbonyls. There is no significant difference in the levels of
protein carbonyls, determined using OxyBlots, in both RIPA buffer-soluble and -insoluble fractions of kidneys between LRRK2-/- mice and wild-
type (+/+) controls at one month of age. But the level of protein carbonyls is significantly reduced in the RIPA buffer-insoluble fractions of
LRRK2-/- kidneys at 7 months of age compared with wild-type controls. By 20 months of age, the level of protein carbonyls is significantly
increased in both RIPA buffer-soluble and -insoluble fractions of LRRK2-/- kidneys. ns, not significant; **, P < 0.01.
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Page 8 of 16Figure 6 Loss of LRRK2 causes accumulation of lysosomal proteins and proteases at all ages examined. A. Representative Western blots
show accumulated levels of lysosomal-associated membrane protein (LAMP-1) and active forms (cathepsins B (catB) and D (catD)) and proforms
(cathepsin D (pro-catD)) of lysosomal proteases involved in the autophagy-lysosomal pathway in the kidneys of 1-, 7-, and 20-month-old LRRK2-/-
mice. All the blots shown here were obtained using RIPA buffer-soluble fractions. Arrows indicate non-specific bands. The Western blots of Rab7
are used as loading control. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001. B. Immunohistochemical analysis revealed increased
immunoreactivity of cathepsin B in the LRRK2-/- kidney at 20 months of age, which is associated with or clustered at granular structures. All scale
bars: 20 μm.
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sent in LRRK2-/- kidneys, consistent with the enhanced
autophagic activity at 7 months of age (Figure 3). How-
ever, autolysosome-like structures in the kidneys of 7-
month-old LRRK2- / -m i c ew e r el a r g e ra n dm o r ea b u n -
dant than those at 4 months of age. By 20 months of
age, we observed in LRRK2-/- kidneys very large to huge
electron-dense lipofuscin granules of typical tripartite
structure composed of three morphologically recogniz-
able components, i.e., irregular electron-lucid compo-
nent, lipid component of intermediate electron-density,
and electron-dense component containing ferritin-like
grains [43], and largely round lipid vacuoles (Figure 7F,
K, &7L). These granules are very different from the elec-
tron-dense autolysosome-like structures that are abun-
dant in the kidney of LRRK2-/- mice at the ages of 7
Figure 7 Electron microscopy analysis of kidneys from LRRK2-/- mice.E Ma n a l y s i ss h o w st h ep r e s e n c eo fm a n ye l e c t r o n - d e n s eb u t
heterogeneous autophagic vacuoles (autophagosomes (double arrows), autolysosomes (single arrows)) at 4 months of age (A, B, G, H), striking
accumulation of giant electron-dense autolysosomes-like structures (single arrows) at 7 months of age (C, D, I, J), and typical tripartite lipofuscin
granules (arrow heads) as well as round lipid vacuoles (asterisks) at 20 months of age (E, F, K, L) in the epithelial cells of the proximal tubules
(see the characteristic brush-like tall microvilli) in the cortical area of the kidneys of LRRK2-/- mice. The images of the bottom row (M, N, O, P)
are higher-magnification views of boxed areas above, showing a lysosome (M), a being-formed autophagosome (double arrowhead; N), a
double membrane-bound autophagosome (double arrow; O), and an autolysosome with an electron dense core (single arrow; P), respectively.
All scale bars: 2 μm.
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lipofuscin-like granules were observed in LRRK2-/- kid-
neys at 7 and 9-10 months of age (data not shown).
These autolysosomes and lipofuscin granules may be the
sources of the strong autofluorescence observed in
LRRK2-/- kidneys (Figure 1C). In addition, normal lyso-
somes were barely observed in LRRK2-/- kidneys at 7,
9-10, and 20 months of age. Our EM analysis of brain
samples from LRRK2-/- mice did not show abnormal
accumulation of autophagosomes, autolysosomes, and
lipofuscin granules, consistent with our previous report
demonstrating the absence of overt neuropathological
c h a n g e s[ 2 6 ] .T o g e t h e rt h e s er e s u l t ss h o wt h a tl o s so f
LRRK2 results in accumulation of lysosomal proteins
and proteases as well as autolysosomes, which eventually
develop into lipofuscin granules (and impair autophagy
function) in aged kidneys.
Discussion
Dominantly inherited mutations in LRRK2 are collec-
tively the most common genetic cause of PD, but its
normal physiological function remains less clear. We
reported previously that loss of LRRK2 causes impair-
ment of the two major protein degradation pathways (i.
e., the autophagy-lysosomal pathway and the ubiquitin-
proteasome system), accumulation and aggregation of
proteins (such as a-synuclein, p62, and ubiquitinated
proteins), and increased apoptotic cell death and inflam-
matory responses in the aged mice, suggesting that
LRRK2 plays an essential role in the regulation of pro-
tein homeostasis [26]. Although these molecular and
cellular changes are observed only in the kidney but not
in the brain of LRRK2-/- mice, they bear striking resem-
blance to processes that are thought to be involved in
PD pathogenesis, suggesting that LRRK2 mutations may
cause Parkinson’s disease and cell death via impairment
of protein degradation pathways, leading to protein
accumulation and aggregation over time. A recent
report shows similar gross morphological abnormalities
in the kidneys of an independent line of LRRK2-/- mice
as well as a line of kinase-dead mutant mice of LRRK2
[44]. The presence of similar kidney phenotypes in at
least four independent lines of LRRK2-/- mice [23,26,44]
suggests that this is unlikely an artifact and that LRRK2
play an important role in the cell.
In the current study, we performed an age-dependent
analysis of LRRK2-/- mice and compared morphological,
ultrastructural, and molecular alterations in LRRK2-/-
mice from 1 month to 20 months of age. We found that
gross morphological abnormalities first become evident
in LRRK2-/- kidneys at 3-4 months of age (Figure 1).
Surprisingly, more detailed analysis revealed that the
autophagic activity appeared enhanced at young age (e.g.
7 months), as evidenced by increased conversion of
LC3-I to LC3-II, a reliable marker of autophagosome
formation [31], and increased degradation of p62, one of
the best characterized autophagy substrates [28], as well
as increased degradation of a-synuclein (Figures 3 and
4). By 20 months of age, similar analysis showed
reduced autophagic activity in LRRK2-/- kidneys (Fig-
ures 3 and 4). However, this age-dependent bi-phasic
alteration of the autophagic activity is accompanied by
progressive accumulation of autolysosomes, reduction of
lysosomes, and the ultimate prevalent presence of large
lipofuscin granules at 20 months of age (Figure 7).
During the normal process of autophagy (here referred
to macroautophagy, the major form of autophagy)
[28,31,41], a portion of cytoplasm, including damaged
proteins and organelles, is first enclosed by isolation
membrane (a double membrane-bound structure) to
form an autophagosome, the outer membrane of which
then fuses with lysosome to form so-called autolyso-
some. The internal material, including proteins and
lipids, is degraded in the autolysosome by acid hydro-
lases originated from lysosomes, and the degradation
products get recycled back to cytoplasm and are to be
used as new building blocks and energy for cellular
renovation and homeostasis [28]. Any disruption along
this process, such as those that affect initiation and
elongation of isolation membrane, autophagosome for-
mation, fusion of autophagosomes and lysosomes, and
hydrolytic degradation, woulda l t e rt h ea u t o p h a g i cf l u x
[ 3 1 ] .O nt h eo n eh a n d ,t h ep r e s e n c eo fal a r g en u m b e r
of autolysosomes is suggestive of enhanced autophagic
flux in LRRK2-/- kidneys at young ages (4, 7, and 9-10
months), consistent with increased protein degradation
at these ages; On the other hand, the unusual accumula-
tion of such structures may also suggest deficits in turn-
over and/or recycling of autophagic components,
leading to accumulation of autolysosomes, which may
evolve into lipofuscin granules through excessive oxida-
tion and crosslinking and eventually result in depletion
of autophagic machinery and therefore impaired autop-
hagic activity at old ages (20 months). Deficient regen-
eration of autophagic lysosomes has been reported to
cause accumulation of autolysosomes [45,46]. Consistent
with this interpretation, compared with wild-type con-
trols, normal lysosomes were rarely observed in proxi-
mal tubules of LRRK2-/- kidneys, where there were
striking accumulation of autolysosomes (at young ages)
and lipofuscin granules (at old ages).
In addition to gross morphological abnormalities
observed in LRRK2-/- kidneys that first become evident
at the age of 3-4 months, the ratio of kidney to body
weight in LRRK2-/- mice significantly increased at
young ages (~10% at 1 month and ~20% at 4 and 7
months) but dramatically decreased at 20 months of age
(~50%, Figure 1). We also observed significantly
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g., LAMP-1, cathepsin B, and cathepsin D, including
active forms and proforms) in LRRK2-/- kidneys begin-
ning as early as one month of age throughout all the
ages examined (Figure 6). One possibility is that loss of
LRRK2 causes induction of autophagy initially via
altered kinase signaling. During autophagy induction,
synthesis of lysosomal proteins and proteases continues
or even up-regulated although other proteins’ synthesis
is generally down-regulated [28]. At older ages, due to a
deficit in clearance or recycling of autolysosomes, the
autolysosome-like structures cannot be digested and
therefore accumulate and evolve into lipofuscin gran-
ules. The increased levels of lysosomal proteins and pro-
teases could be from the accumulated autolysosome-like
structures or indigestible lipofuscin granules, both of
which contain components originated from lysosomes,
including lysosomal proteins and proteases, since the
number of lysosomes is not increased, but decreased
instead.
Deficits in autophagy have been implicated in a vari-
ety of neurodegenerative diseases with protein aggrega-
tion-related pathologies [27,29,47]. Interestingly,
increased accumulation of autophagic vacuoles, includ-
ing both autophagosomes and autolysosomes, has also
been reported in postmortem brains of Alzheimer’s
and Parkinson’s disease patients, with likely reasons of
either overproduction of autophagic vacuoles or deficit
in clearance or recycling of autolysosomes [29,48].
Cathepsin D is also up-regulated in affected neurons.
Antibodies to cathepsin D strongly label contents in
some of the accumulated autophagic vacuoles, which
a r ei d e n t i f i e da sa u t o l y s o s o m e s ,a sw e l la st h ep r o t e i -
naceous components of lipofuscins [48]. Our data
demonstrate that the autophagy-lysosomal pathway is
dysregulated in the absence of LRRK2. Although loss
of LRRK2 may initially cause induction of autophagy,
deficient clearance or recycling of autophagic compo-
nents in the absence of LRRK2 would cause trapping
of the components of the autophagy pathway in the
forms of autolysosomes and the eventual formation of
lipofuscin granules due to excessive oxidation and
crosslinking and therefore depletion of autophagy
machinery (e.g., autophagic lysosomes cannot be
reformed.), which would in turn result in accumulation
and aggregation of a large number of autophagy sub-
strate proteins during aging (Figure 8). Likely as a con-
sequence or a response to the stresses presumably
rendered by the above discussed abnormalities,
LRRK2-/- kidneys sustain chronic injury, indicated by
dramatic and persistent up-regulation of kidney injury
molecule-1 (Figure 2), a very sensitive and specific bio-
marker for epithelial cell injury of proximal renal
tubules in various settings [33,34].
Although these molecular and cellular changes are
observed only in the kidney but not in the brain of
LRRK2-/- mice, they are very similar to processes that
have been implicated in pathogenesis of PD and other
neurodegenerative diseases, making LRRK2-/- kidneys a
relevant and valuable in vivo model, which provides a
physiological setting for the studies of LRRK2 function
and the identification of the cellular pathways that
LRRK2 pathogenic mutations may affect. More ques-
tions await further investigation using this unique
LRRK2-/- kidney as a model. For example, how does
loss of LRRK2 cause bi-phasic alteration of autophagic
activity? How does loss of LRRK2 lead to autophagy
induction as well as deficits in clearance and/or regen-
eration of autophagy components? Interestingly, it has
recently been reported that siRNA knockdown of
LRRK2 increases autophagic activity and the R1441C
mutation in LRRK2 induces accumulation of autophagic
vacuoles of enlarged size in cultured HEK293 cells [49].
Surprisingly, LRRK2 overexpression in cultured HEK293
cells has also been reported to cause autophagy induc-
tion through a calcium-dependent pathway [50].
Although these results may seem contradictory with
each other, which may be due to the fact that these stu-
dies were performed in cell culture systems using
immortalized cell lines, rather than an in vivo
Figure 8 A schematic model for bi-phasic dysregulation of
autophagic activity by loss of LRRK2. Loss of LRRK2 initially
causes induction of autophagy, but later leads to autolysosome
accumulation and depletion of the autophagy machinery due to
trapping of autophagic components in the form of autolysosomes
and the eventual formation of lipofuscin granules, which would in
turn result in accumulation and aggregation of a large number of
autophagy substrate proteins during aging.
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LRRK2 is important for the dynamic regulation of
autophagy function. LRRK2 has also been reported to
localize to specific membrane subdomains, including
autophagosomes and autolysosomes [49], suggesting
that LRRK2 may directly participate in the dynamic pro-
cess, including formation and clearance, of autophagic
vacuoles. What is the role of aging process, which can-
not be mimicked in cell culture systems, in this bi-pha-
sic dysregulation of autophagic activity by loss of
LRRK2? In addition, LRRK2 has been implicated in both
transcriptional and translational regulation [51,52]. Is
protein synthesis besides degradation also affected in the
absence of LRRK2? Last but not the least, why are these
PD-like cellular changes present only in the kidney but
n o ti nt h eb r a i no fLRRK2-/- mice? One possibility is
that LRRK2-/- kidneys suffer the greatest loss of LRRK
protein (LRRK1 + LRRK2) because the kidney not only
has the highest expression level of LRRK2 compared to
other organs (5-fold higher than the brain), but also has
the least overlapping expression pattern between LRRK2
and LRRK1 [53], the other member of the LRRK family.
This may explain why LRRK1 does not compensate for
the loss of LRRK2 in the kidney, and loss of LRRK2
causes impairment of the protein degradation pathways
and striking age-dependent kidney abnormalities. In the
brain, LRRK1 may be able to compensate for the loss of
LRRK2. This interpretation is supported by the finding
that in the developing brain the expression level of
LRRK1 is much higher than that of LRRK2,a n di ti s
broadly expressed [53,54]. We are currently in the pro-
cess of generating LRRK1/LRRK2-deficient mice to
determine whether complete loss of LRRK in neurons,
especially in dopaminergic neurons where oxidative
stress is elevated, results in age-dependent protein
aggregation, autophagy alteration, and neurodegenera-
tion. Future studies aimed at addressing these important
questions under a physiological setting using our unique
LRRK2-/- kidney as a model would no doubt help us
better understand the normal physiological function of
LRRK2 and its role in PD pathogenesis.
Conclusions
Our latest studies of age-dependent development of
phenotypes in LRRK2-/- kidneys show that LRRK2 is
required for normal regulation of the autophagy-lysoso-
mal pathway. Loss of LRRK2 causes impairment of the
protein degradation pathways and striking age-depen-
dent cellular changes in the kidney, which are similar to
PD pathogenesis, making the LRRK2-/- kidney a unique
and valuable model for elucidating the normal physiolo-
gical role of LRRK2 under its physiological settings.
LRRK2 mutations may cause Parkinson’s disease and
cell death by impairing protein degradation pathways,
leading to protein accumulation and aggregation over
time.
Methods
LRRK2-/- mice
The generation and initial characterization of two inde-
pendent lines (KO1 and KO2) of LRRK2-/- mice have
been described previously [26]. The mice used in this
study were obtained by intercrossing heterozygous litter-
mate mice, which were maintained on B6/129 genetic
background. All mouse work follows the protocol
approved by Harvard Center for Animal Resources and
Comparative Medicine.
Histological and immunohistochemical analysis
Each mouse was anesthetized by intraperitoneal injec-
tion of sodium pentobarbital 15 min after injection of
heparin (500 units in saline). The mouse was then trans-
cardially perfused with 20 ml of Ringer’s solution con-
taining 0.25 g/L heparin and 5 g/L procaine followed by
25 ml of ice-cold 4% paraformaldehyde in 1× phosphate
buffered saline (pH 7.4). The kidneys were dissected out
and post-fixed in 4% paraformalhehyde at 4°C overnight
and then processed for paraffin embedding following
standard procedures. Kidney sections were cut at 8 μm.
For immunohistochemical analysis, some tissue sections
were subjected to antigen retrieval by microwaving or
autoclaving for 10 or 15 min in 10 mM sodium citrate
buffer, pH 6.0. Endogenous peroxidase activity was
quenched by incubating in 0.3% H2O2 in methanol.
After blocking, sections were incubated with primary
antibodies overnight at 4°C, followed by 1-h incubation
with biotinylated secondary antibodies and 1-h incuba-
tion with Vectastain Elite ABC reagent and then devel-
oped using chromogenic DAB substrate (Vector
Laboratories). For negative controls, primary antibodies
alone or together with secondary antibodies were
omitted from the incubation buffer.
Transmission electron microscopy analysis
Mice were perfused following a procedure similar to
that for histological and immunohistochemical analysis
above except a mixture of 2.5% paraformaldehyde and
2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer
(pH 7.4) was used as the fixative. After overnight post-
fixation at 4°C, the dissected tissues were then trimmed
to 1-2 mm
3 cubes and left in the fixative until proces-
sing for embedding in resin. Embedding was performed
and ultrathin (60-80 nm) sections were cut by the Har-
vard Medical School EM facility following a routine pro-
tocol. EM images of ultrathin sections were collected on
a Tecnai G
2 Spirit BioTWIN electron microscope. Some
o ft h et i s s u e sf r o mt h em i c ea t9 - 1 0a n d2 0m o n t ho f
age used for EM analysis were from a third independent
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also show similar kidney morphological phenotypes.
Measurement of blood urea nitrogen and serum
creatinine
Approximately 0.3 ml of blood was collected from each
mouse as described previously [34]. Briefly, mice were
anesthetized by intraperitoneal injection of sodium pen-
tobarbital, and blood was collected into heparinized
micro-hematocrit capillary tubes by nicking the tail vein
of the anesthetized mice near the tip of the tail. Serum
was prepared from the collected blood samples and
stored at -80°C. Blood urea nitrogen and serum creati-
nine were measured following the classical methods for
renal chemistry as describe previously [34].
Preparation of RIPA buffer-soluble and -insoluble
fractions
Fresh mouse kidneys were homogenized in an ice-cold
stringent RIPA buffer (50 mM Tris-HCl, pH 7.4, 150
m MN a C l ,0 . 1 %S D S ,1 %T r i t o nX - 1 0 0 ,1 %s o d i u m
deoxycholate, supplemented with protease inhibitor
mixture and phosphatase inhibitor mixtures), followed
by sonication. Homogenates were centrifuged at 14,000
× g for 20 min at 4°C to separate supernatants (RIPA
buffer-soluble fractions). The resulting pellets were
further lysed with a buffer containing 4% SDS and 20
mM HEPES, pH 7.5, supplemented with protease inhibi-
tor mixture and phosphatase inhibitor mixtures by vor-
texing and sonication, followed by centrifugation at
19,600 × g for 10 min at room temperature to separate
the new supernatants (RIPA buffer-insoluble fractions).
Western blotting and OxyBlot
Equal amount of total proteins from each preparation
was loaded and separated in NuPAGE 3-8% Tris-Acetate
gels or 4-12% Bis-Tris gels (Invitrogen) and then trans-
ferred to nitrocellulose membranes. Oxyblots for detect-
ing protein carbonyls were prepared following the
manufacturer’s instructions (Millipore). After blocking
and overnight incubation with primary antibodies, pro-
tein bands of interest were visualized by binding of
IRDye-labeled secondary antibodies and band intensity
analyzed using Odyssey imaging system (Li-Cor).
Antibodies
Antibodies used in Western blotting and/or immunohis-
tochemical analyses are: goat pAb anti-mouse Kim-1
(R&D Systems), rabbit pAb anti-ERK1/2 (p44/42 MAP
kinase; Cell Signaling), rabbit pAb anti-LC3B (Sigma or
Cell Signaling), rabbit pAb anti-GATE-16 (MBL), guinea
pig pAb anti-p62 (Progen), rabbit pAb anti-p62 (Wako),
rabbit pAb anti-a-synuclein (C-20; Santa Cruz), rabbit
pAb anti-LAMP-1 (Cell Signaling), rat mAb anti-LAMP-
1 (University of Iowa), rat mAb anti-LAMP-2 (Univer-
sity of Iowa), rabbit pAb anti-cathepsin B (Santa Cruz),
rabbit pAb anti-cathepsin D (Calbiochem), rabbit pAb
anti-Rab7 (Cell Signaling), mouse mAb anti-GAPDH
(Millipore), rabbit pAb anti-b-actin (Cell Signaling),
mouse mAb anti-b-actin (Sigma).
Statistical Analysis
Statistical analysis was performed using Prism 5 (Graph-
Pad Software) and Excel (Microsoft). Data are presented
as means ± SEM. Statistical significance was determined
by the P values of Student t test. Asterisks denote statis-
tical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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